Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of “Moderate Buy” by Brokerages

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $56.7143.

Several research firms have recently issued reports on IMCR. Zacks Research raised Immunocore from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Mizuho set a $38.00 price objective on Immunocore in a research note on Thursday, February 19th. Jefferies Financial Group lowered Immunocore from a “buy” rating to a “hold” rating and lowered their price objective for the company from $48.00 to $33.00 in a research note on Monday, March 16th. Wall Street Zen raised Immunocore from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st.

Institutional Investors Weigh In On Immunocore

Several institutional investors have recently modified their holdings of the stock. Stempoint Capital LP bought a new stake in shares of Immunocore in the 1st quarter valued at approximately $1,916,000. Janus Henderson Group PLC lifted its stake in shares of Immunocore by 30.9% during the 1st quarter. Janus Henderson Group PLC now owns 594,712 shares of the company’s stock worth $17,919,000 after acquiring an additional 140,308 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Immunocore by 5.2% during the 1st quarter. Royal Bank of Canada now owns 44,714 shares of the company’s stock worth $1,348,000 after acquiring an additional 2,228 shares during the last quarter. Eversept Partners LP bought a new stake in shares of Immunocore during the 1st quarter worth approximately $1,183,000. Finally, Entropy Technologies LP bought a new stake in shares of Immunocore during the 1st quarter worth approximately $302,000. 84.50% of the stock is owned by institutional investors.

Immunocore Price Performance

Shares of Immunocore stock opened at $28.96 on Friday. The stock has a 50 day moving average of $29.61 and a 200 day moving average of $32.33. Immunocore has a 12 month low of $27.56 and a 12 month high of $40.71. The firm has a market cap of $1.47 billion, a PE ratio of -52.65 and a beta of 0.74. The company has a current ratio of 4.18, a quick ratio of 4.15 and a debt-to-equity ratio of 1.00.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.51. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The company had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. During the same period in the prior year, the company earned $0.10 earnings per share. The firm’s revenue was up 13.6% on a year-over-year basis. On average, research analysts expect that Immunocore will post 0.06 EPS for the current fiscal year.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.